Abstracts tagged "Disease-Modifying Antirheumatic Drugs (Dmards)"

Abstract Number: 0524 • ACR Convergence 2024
Evaluating Dose Reduction of Biologic Treatments in Rheumatoid Arthritis: Predicting Flares Using Clinical and Molecular Biomarkers
Laura Galindo Domínguez¹, Belen Acasuso², Vanesa Balboa-Barreiro³, Juan Fernández-Tajes², Juan Cañete⁴, Benjamin Fernández-Gutiérrez⁵, Isidoro González-Álvaro⁶, José L Pablos⁷, Carmen Bejerano-Herreria⁸, Maite Silva-Díaz⁹, Franciso javier De-Toro-Santos², Natividad Oreiro¹⁰ and francisco J Blanco¹¹, ¹Instituto de Investigacion Biomedica de A Coruña (INIBIC), A Coruña, Spain, ²Unidad de Investigacion Clinica. Grupo de Investigación de Reumatología (GIR). Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas., Investigation, A Coruña, Spain, A Coruña, Spain, ³Unidad de Epidemiología Clínica y Bioeostadística. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC)., A Coruña, Spain, ⁴Hospital Clinic an IDIBAPS, Barcelona, Spain, ⁵3Rheumatology Department, and Health Research Institute (IdISSC), Hospital Clínico San Carlos, Calle del Profesor Martín Lagos, s/n, 28040, Madrid, Spain., Rheumatology, Madrir, Spain, Madrid, Madrid, Spain, ⁶University Hospital La Princesa, Madrid, Madrid, Spain, ⁷Health ministry, Madrid, Madrid, Spain, ⁸Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁹Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain, ¹⁰CHUAC, La Coruna, Galicia, Spain, ¹¹INIBIC-University of A Coruña, A Coruña, Spain
Background/Purpose: Reducing the dosage of biologic drugs in patients with rheumatoid arthritis (RA) who have achieved remission is a viable and necessary strategy. To identify…
Abstract Number: 0899 • ACR Convergence 2024
Proteomic Insights into JAK Inhibitor Therapeutic Response in Rheumatoid Arthritis
Ting-Shuan Wu¹ and Yi-Ming Chen², ¹Chung Shan Medical University, Taichung, Taiwan (Republic of China), ²Taichung Veterans General Hospital, Taiwan, Taichung, Taiwan (Republic of China)
Background/Purpose: Rheumatoid arthritis (RA) is a common and complex inflammatory polyarthritis. Janus kinase inhibitors (JAKi) have shown superior efficacy compared to traditional treatments, but predictors…
Abstract Number: 1370 • ACR Convergence 2024
Upadacitinib vs TNFi and Other JAKi Treatment Outcomes in Australian Rheumatoid Arthritis Patients: Descriptive Comparison of Persistence and Effectiveness Using the OPAL Dataset
Sabina Ciciriello¹, Peter Youssef², Talib Tahir³, Tegan Smith⁴, Catherine O'Sullivan⁴, Joanna Leadbetter⁵, Belinda Butcher⁵, Miriam Calao⁶, Nicole Walsh⁶ and Geoffrey Littlejohn⁷, ¹The University of Melbourne, Melbourne, Victoria, Australia, ²Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia, ³Coburg Rheumatology Service, Coburg, Victoria, Australia, ⁴OPAL Rheumatology Ltd, Geelong, Victoria, Australia, ⁵WriteSource Medical Pty Ltd, Lane Cove, New South Wales, Australia, ⁶AbbVie Pty Ltd, Mascot, New South Wales, Australia, ⁷Monash University, Clayton, Victoria, Australia
Background/Purpose: To descriptively compare treatment patterns, persistence and effectiveness of upadacitinib (UPA), other JAK inhibitors (JAKi) and tumour necrosis factor inhibitors (TNFi) in rheumatoid arthritis…
Abstract Number: 1540 • ACR Convergence 2024
Project HOPE: HydrOxychloroquine Adherence ProjEct
Meredith LiCalzi¹, Fotios Koumpouras² and Jacinta Renaldi³, ¹Frank H. Netter MD School of Medicine at Quinnipiac University, North Haven, CT, ²Yale School of Medicine, New Haven, CT, ³Yale New Haven Hospital, New Haven, CT
Background/Purpose: Hydroxychloroquine (HCQ) is known to reduce flares, improve disease activity and mortality in patients with systemic lupus erythematosus (SLE).1 Nonadherence to HCQ is a noteworthy…
Abstract Number: 1902 • ACR Convergence 2024
Ixekizumab for the Treatment of Patients with Spondyloarthritis – Real-world Evidence from the Nationwide Danish Registry, DANBIO
Kasper Yde Jensen¹, Merete Hetland² and Bente Glintborg³, ¹Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark, ²DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark, Glostrup, Denmark, ³DANBIO, Rigshospitalet Glostrup and University of Copenhagen, Virum, Denmark
Background/Purpose: Clinical trials have provided robust evidence of the efficacy of ixekizumab, an IL-17 inhibitor, in improving the signs and symptoms of psoriatic arthritis (PsA)…
Abstract Number: 2316 • ACR Convergence 2024
Gene Expression Profile Is Different Between Men and Women in Psoriatic Disease
Pauline KRUG¹, angela De Sousa Leite², Frédéric Lecouvet¹, Maria Simona stoenoiu¹ and Adrien Nzeusseu Toukap³, ¹Cliniques universitaires St-Luc, Brussel, Belgium, ²Cliniques universitaires St-Luc, Brussels, Belgium, ³Cliniques universitaires Saint-Luc,, St.-Lambrechts-Woluwe, Belgium
Background/Purpose: Psoriatic arthritis (PsA) is a highly heterogenous chronic inflammatory condition. Recent publications highlight differences between men and women in disease manifestation and response to…
Abstract Number: 0360 • ACR Convergence 2024
What Happens in Rheumatoid Arthritis Treatment Adherence, Two Years After the Introduction of Targeted Therapy? Results from the STRATEGE2 Study
Cécile Gaujoux-Viala¹, Emmanuelle Dernis², Eric Senbel³ and René-Marc Flipo⁴, ¹CHU Nîmes, Nïmes, Languedoc-Roussillon, France, ²CH LE MANS, LE MANS, Pays de la Loire, France, ³Cabinet de Rhumatologie, Marseille, France, ⁴Hôpital Roger Salengro, France, Lille, France
Background/Purpose: Treatment adherence is a major challenge in chronic inflammatory rheumatic diseases, particularly rheumatoid arthritis (RA), with adherence rates ranging from 30 to 80%. Given…
Abstract Number: 0525 • ACR Convergence 2024
Assess the Effect of Increasing the Dose of Folic Acid Supplementation in Patients of Rheumatoid Arthritis with Methotrexate Intolerance – A Randomised Controlled Trial
Varun Dhir¹, Harshith Sai Koneti², Aman Sharma³, sanjay jain⁴ and shankar naidu⁵, ¹PGIMER, CHD, INDIA, CHANDIGARH, India, ²PGIMER, Chandigarh, Sangareddy, Telangana, India, ³PGIMER, Chandigarh, India, Chandigarh, Chandigarh, India, ⁴PGIMER, Chandigarh, Chandigarh, India, ⁵PGIMER, Chandigarh, India, Chandigarh, India
Background/Purpose: : Methotrexate (MTX) Intolerance continues to occur in 20-40% patients despite low-dose folic acid (5-10mg per week) supplementation. Would a higher dose of folic…
Abstract Number: 1000 • ACR Convergence 2024
Adalimumab Biosimilar-to-biosimilar Switch in Patients with Inflammatory Rheumatic Diseases – Real-world Evidence from the Nationwide Danish Registry, DANBIO
Kasper Yde Jensen¹, Hafsah Nabi², Dorte Vendelbo Jensen³, Jens Pedersen⁴, Oliver Hendricks⁵, Anne Gitte Loft⁶, Ada Colic⁷, Kamilla Danebod³, Salome Kristensen⁸, Heidi Munk⁹, Niels Lomborg¹⁰, Natalia Manilo¹¹, Stavros Chrysidis¹², Søren Just¹³, Asta Linauskas¹⁴, Pil Højgaard¹⁵, Pia Høger Thygesen¹⁶, Malene Kildemand¹⁷, Rene Drage Oestgaard¹⁸, Merete Hetland¹⁹ and Bente Glintborg²⁰, ¹Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark, ²DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Rigshospitalet, Copenhagen, Denmark, Glostrup, Denmark, ³Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Rigshospitalet, Glostrup, Denmark, ⁴Department of Rheumatology C, Research Unit, Odense University Hospital and Department of Clinical Research, University of Southern Denmark, Odense, Denmark, ⁵Danish Hospital For Rheumatic Diseases, Sønderborg, Denmark, ⁶Department of Rheumatology, Aarhus University Hospital and Aarhus University, Aarhus, Denmark, ⁷Department of Rheumatology, Zealand University Hospital, Koege, Denmark, ⁸Centre of Rheumatic Research Aalborg, Department of Rheumatology and Aalborg University Hospital and Department of Clinical Medicine, Aalborg University, Aalborg, Denmark, ⁹Department of Rheumatology, Odense University Hospital, Odense, Denmark and Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, ¹⁰Department of Rheumatology, Vejle Hospital Lillebælt, Odense C, Denmark, ¹¹Department of Rheumatology, Frederiksberg Hospital, Copenhagen, Denmark, ¹²Department of Rheumatology, University Hospital of Southern Denmark, Esbjerg, Denmark, ¹³Medicinsk Afdeling Svendborg Sygehus OUH, Odense, Denmark, ¹⁴Department of Rheumatology, North Denmark Regional Hospital, Hjoerring, Denmark and Department of Clinical Medicine, Aalborg University, Aalborg, Denmark, ¹⁵Department of Internal Medicine 2; Rheumatology, Holbæk Sygehus, Holbæk, Denmark and Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Frederiksberg Hospital, Copenhagen, Denmark, ¹⁶Department of Rheumatology, Slagelse Hospital, Slagelse, Denmark, ¹⁷Department of Rheumatology, Odense University Hospital, Svendborg, Denmark, ¹⁸Department of Medicine, Goedstrup Regional Hospital and Diagnostic Center, Silkeborg Regional Hospital, Silkeborg, Denmark, ¹⁹DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark, Glostrup, Denmark, ²⁰DANBIO, Rigshospitalet Glostrup and University of Copenhagen, Virum, Denmark
Background/Purpose: In Denmark, mandatory switches between originators and corresponding biosimilar products have been performed for economic reasons for nearly a decade (1). Starting in January…
Abstract Number: 1371 • ACR Convergence 2024
DMARD Utilization Pattern in Older Adults with Rheumatoid Arthritis
Daniela Seelmann¹, Jiha Lee² and Devyani Misra³, ¹Beth Israel Deaconess Medical Canter, Newton, MA, ²University of Michigan, Ann Arbor, MI, ³Beth Israel Deaconess Medical Center, Boston, Boston, MA
Background/Purpose: Disease modifying anti-rheumatic drug (DMARD) use in older adults with rheumatoid arthritis (RA) is challenging due to unique geriatric issues, such as multimorbidity, polypharmacy,…
Abstract Number: 1582 • ACR Convergence 2024
Impact of Immunosuppressive Treatment on Development and Survival in Systemic Sclerosis Associated Pulmonary Arterial Hypertension (SSc-PAH)
Stefano Rodolfi¹, Cheryl Chun Man Ng², Ana Maria Ruiz Bejerano², Medha Kanitkar², Voon Ong³ and Christopher Denton⁴, ¹Centre for Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom, ²University College London, London, United Kingdom, ³University College London, London, England, United Kingdom, ⁴University College London, Northwood, United Kingdom
Background/Purpose: Pulmonary arterial hypertension (PAH) is a severe and frequently life-threatening complication of systemic sclerosis (SSc). Treatment of SSc-PAH follows the same approach of idiopathic…
Abstract Number: 1980 • ACR Convergence 2024
Efficacy and Safety of Methotrexate in Immune Checkpoint Inhibitor-induced Arthritis: A Retrospective Longitudinal Monocentric Study
Elvis Hysa¹, Andrea Casabella², Nicola Iandolino³, Emanuele Gotelli⁴, Carlo Genova³, Enrica Teresa Tanda³, Carmen Pizzorni⁵, vanessa smith⁶, Alberto Sulli⁷, Maurizio Cutolo⁴ and Sabrina Paolino⁸, ¹Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, Genoa, Italy, ²Ospedale Policlinico San Martino, Genoa, Italy, ³University of Genoa, Ospedale Policlinico San Martino, Genoa, Italy, ⁴Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, Genova, Italy, ⁵Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, Genoa, Italy, ⁶Ghent University Hospital, Gent, Belgium, ⁷Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy., Genova, Italy, ⁸Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine and Specialties (Di.M.I.), University of Genova; IRCCS Ospedale Policlinico San Martino, Genova, Liguria, Italy
Background/Purpose: The management of immune-mediated adverse events (irAEs) during treatment with immune checkpoint inhibitors (ICIs) involves high dosages of glucocorticoids (GCs). Despite being effective in…
Abstract Number: 2317 • ACR Convergence 2024
Chronic Kidney Disease in Patients with Psoriatic Arthritis: A Cohort Study
Fadi Kharouf¹, Shangyi Gao², Shahad Al-Matar³, Daniel Pereira⁴, Richard Cook⁵, Vinod Chandran⁶ and Dafna Gladman⁷, ¹University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, ²Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ³Toronto Western Hospital, University of Toronto, Toronto, Canada, ⁴University Health Network, Toronto, ON, Canada, ⁵University of Waterloo, Waterloo, Canada, ⁶University of Toronto, Toronto, ON, Canada, ⁷University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Chronic kidney disease (CKD) is a comorbidity in psoriatic arthritis (PsA). In this study, we aimed to define the prevalence of CKD in patients…
Abstract Number: 0367 • ACR Convergence 2024
Opinions from Rheumatoid Arthritis Patients and Providers on Discontinuing Methotrexate in Stable Disease
Peri Newman¹, Sharon Banks¹, Rayford June², Erik Lehman³, Glennys Smith⁴, Vandana Rai⁴, Nicole Wilson⁴, Nancy Olsen⁵ and Tarun Sharma⁴, ¹Penn State Health, Hershey, PA, ²Penn State College of Medicine/Lebanon VA Medical Center, Hummelstown, PA, ³Penn State College of Medicine, Hershey, PA, ⁴Allegheny Health Network, Pittsburgh, PA, ⁵Penn State University/Milton S Hershey, Hershey, PA
Background/Purpose: The 2021 American College of Rheumatology guidelines for treatment of rheumatoid arthritis (RA) conditionally recommend a gradual discontinuation of methotrexate (MTX) over biologic discontinuation.…
Abstract Number: 0529 • ACR Convergence 2024
Discontinuation of Targeted Disease-Modifying Antirheumatic Agents in Older Patients with Rheumatoid Arthritis: Retrospective Analysis of Medicare Data
Yinan Huang¹, Shadi Bazzazzadehgan², Sebastian Bruera³ and Sandeep Agarwal³, ¹University of Mississippi School of Pharmacy, Oxford, MS, ²University of Mississippi School of Pharmacy, Oxford, ³Baylor College of Medicine, Houston
Background/Purpose: Individuals with rheumatoid arthritis (RA) may discontinue b/tsDMARDs due to treatment failure, adverse events or costs. Little is known about b/tsDMARDs discontinuation among Medicare…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].